Inflammatory disease Archives

abbvie ablynx rheumatoid arthritis nanobody

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

tigenix takeda stem cell therapy crohns fistula

News and Trends 6 Jul 2016

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

TiGenix is licensing the rights for its cell therapy which is under EMA review and is meant to treat a serious complication of Crohn’s disease. This worldwide exclusivity deal (with exception to the US) could be worth up to €380M. Back in 2009, Leuven-based TiGenix was the first to launch at cell-based product (ChondroCellect) on the European market. […]

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 9 Jun 2016

German Biotech launches Phase II in a hot Target for Inflammation

InflaRx has treated the first patient in a new Phase II trial, which is studying the potential of its anti-complement antibody in avoiding immunological complications after complex cardiac surgery – a big unmet need. It is competing with world most expensive drug Soliris from Alexion (US). Based in Jena (Germany), InflaRx specializes in developing new […]

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 26 May 2016

French T-cell Expert restarts trial for Crohn’s after Manufacturing Hiccup

TxCell is restarting its trial for Ovasave, an autologous T-cell therapy, with a new manufacturing partner. This therapy is targeting Crohn’s disease which does not respond to current treatments. TxCell is based in Sophia-Antipolis (France) and is developing immunotherapies based on a type of T-cells that have anti-inflammatory properties – regulatory T-lymphocytes (Tregs). Its most advanced programme is in refractory Crohn’s […]

May 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 13 May 2016

Biotech of the Week: Avexxin, reducing inflammatory diseases from far up in Norway

We’re not going particularly far this week and we aren’t even leaving Scandinavia! From Stockholm, we are crossing the border to Norway and go up North. Sadly it’s not the see the Northern Lights but to visit Trondheim, where Avexxin, our Biotech of the Week is located. City: Trondheim (Norway) Founded: 2005 Employees: 8 (as of […]

May 13, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 22 Apr 2016

Biotech of the Week: Covagen, binding proteins to antibodies for Immunotherapy

We say our goodbyes to Belgium this week and head one more time to Switzerland. In Zürich, where you can find almost any kind of cheese, delicious chocolate and a beautiful view of the Swiss Alps near the city lake, is also where Covagen, our Biotech of the Week is located. City: Zürich (Switzerland) Founded: 2007 Employees: 23 (as of […]

April 22, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Apr 2016

French Microbiome Therapy boosted by compound from major US Biotech

Enterome, a leader in the European microbiome field, has struck a deal with US’ Vertex to develop novel small molecules with potential to treat inflammatory bowel diseases. With an impressive roll of partnerships and backed by the world-first Microbiome fund, Enterome is very well-positioned in hype field of the Microbiome. We discussed Enterome’s differentiated strategy […]

April 19, 2016 - 3 minutesmins - By Denise Neves Gameiro

gsk morphosys hand osteoarthritis rheumatoid

News and Trends 19 Apr 2016

GSK goes to phase II with German Antibody for Inflammatory Diseases

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165. The trial will enroll 40 patients with hand osteoarthritis – a condition that damages […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

samsung bioepis biotech rheumatoid arthritis biosimilar flixabi sb4

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi, a biosimilar of Janssen’s blockbuster Remicade for Inflammatory diseases. Samsung Bioepis is a joint venture between Biogen and Samsung BioLogics, a branch of the Korean giant that provides manufacturing services for development of biologicals. It started developing […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

capella biosciences medicxi ventures advent life sciences osage university partners mabs monoclonal antibodies oncology autoimmune target biology

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Nanobody Phase II Results for Arthritis: Good but not good enough?

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

German Biotech launches Phase II in a hot Target for Inflammation

French T-cell Expert restarts trial for Crohn’s after Manufacturing Hiccup

Biotech of the Week: Avexxin, reducing inflammatory diseases from far up in Norway

Biotech of the Week: Covagen, binding proteins to antibodies for Immunotherapy

French Microbiome Therapy boosted by compound from major US Biotech

GSK goes to phase II with German Antibody for Inflammatory Diseases

Two of the Biggest European Biotechs launch Antibody Program together

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!